argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
April 28 2022 - 1:00AM
April 28, 2022Breda,
the Netherlands – argenx (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases, today announced
that it will host a conference call and audio webcast on Thursday,
May 5, 2022 at 2:30 pm CET (8:30 am ET) to discuss its first
quarter 2022 financial results and provide a business update.
A webcast of the live call may be accessed on
the Investors section of the argenx website at
argenx.com/investors. A replay of the webcast will be available on
the argenx website for approximately one year following the
call.
Dial-in numbers:Use the access
code 073235 to join the call. Please dial in 15 minutes prior to
the live call.
Belgium 32
800 548 13United
Kingdom 44 808 189
6484United States
1
844 200 6205All other
locations 1 929 526
1599
About argenx
argenx is a global immunology company committed
to improving the lives of people suffering from severe autoimmune
diseases. Partnering with leading academic researchers through its
Immunology Innovation Program (IIP), argenx aims to translate
immunology breakthroughs into a world-class portfolio of novel
antibody-based medicines. argenx developed and is commercializing
the first-and-only approved neonatal Fc receptor (FcRn) blocker in
the U.S. and Japan. The Company is evaluating efgartigimod in
multiple serious autoimmune diseases and advancing several earlier
stage experimental medicines within its therapeutic franchises. For
more information, visit www.argenx.com and follow us on LinkedIn,
Twitter, and Instagram.
For further information, please
contact:
Media:
Kelsey Kirkkkirk@argenx.com
Investors:
Beth DelGiaccobdelgiacco@argenx.com
Michelle Greenblattmgreenblatt@argenx.com
argenx (NASDAQ:ARGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
argenx (NASDAQ:ARGX)
Historical Stock Chart
From Jul 2023 to Jul 2024